William Austen: Thank you, Mike, and good morning, everyone. As I look at the big picture, I see us moving our business in the right direction. Many of the numbers reflected were delivering strong EPS improvement, our highest levels of EBITDA in years, increasing margins and ROIC and robust cash flow. These things don't happen by accident. And I applaud the hard work of our 18,000 employees across the globe in delivering these results. Top of mind for me is our commitment to create long-term, sustainable shareholder value. To do that effectively requires every single one of our employees to be aware and engaged in the cause and armed with the tools needed to do their jobs effectively. While we've made progress, there is still work to do to drive accountability further into the organization, to deepen the sense of urgency in meeting our financial commitments, and to improve our processes and tools used to support our business goals. Let me provide you a few examples of the new ways we're strengthening our business for the long-term. First, related to our commercialization process. We have brought in an outside firm to review this process end-to-end during the fourth quarter. The commercialization delays in our U.S. business this quarter that we caused due to our internal processes being slow and cumbersome are unacceptable. I get the fact that customers sometimes are slow in ramping-up new business but when we have inefficiency in our system that's just not okay. So, we're launching this project to review all the touch points, all the weak links in the process, all the ways we can remove obstacles, so that new business can be commercialized on pace to our forecasts. Second, bringing in new people. This doesn't mean adding head count or additional SG&A costs. This means that when the opportunity or need arises, we will bring in new thinking and diverse experience from outside of Bemis to help drive change within the organization to deepen the sense of urgency and intensify our drive to win. A relevant example is the recent leadership change in our Healthcare Packaging business. After 20 plus years of dedicated and meaningful service to Bemis, the President of Healthcare Packaging business, Paul Verbeten, is retiring. Our new President of Healthcare Packaging, Jorg Schneewind, comes to Bemis with experience in the medical device industry. And I look forward to Jorg's leadership in bringing our Healthcare Business to the next level. We also welcomed a new Vice President of Operations for our Healthcare Packaging business, Chris McHugh. I look forward to the impact Chris will have on improving operational efficiencies and delivering the expected returns on the investments we've made in our Healthcare business. And the third example of ways we're supporting our business for the long-term, we're fortifying our business development initiatives. Jim Ward recently joined Bemis as Vice President of Corporate Development to strengthen and accelerate our inorganic growth strategy. Jim is a former investment banker who has spent the past several years as a Business Development Director at a large consumer packaged goods company. I'm confident that the addition of Jim will support our external commitment to grow Bemis Company revenue 3% inorganically by 2019. To be clear, I'm proud of the progress our teams across the globe have made to-date. Change continues. And I will continue to take action and do everything possible to help us deliver our long-term commitments to make Bemis successful. Turning to outlook. We do remain committed to our long-term financial objectives. Most of our metrics are moving in the right direction. However, we can't run away from the lack of volume growth in U.S. Packaging and our operational issues in Global Packaging. These two topics are front and center at our company today and resolving both is important in meeting our long-term EPS targets. While our 2016 guidance range doesn't meet our 10% EPS growth objective, we're determined to get back on track to achieving this annual target going forward. I remain very confident in the health of our business, in our drive to change the culture, and in our ability to deliver improvement. With that, I'll turn the call over for questions.
William Austen: Yeah. Good morning, Anthony. This is Bill. If you were to look at in total, we would look at 60% of the misses were controllable by us, 40% were extended launches from customers that might have had an issue and a factor in a plant, a late startup related to a customer. However, that 60% were issues we had internally where we couldn't and didn't get the product launched and/or commercialized through our system. And that's why we're bringing in the external consultant. We're going to have them look at the end-to-end commercialization process that we have within the company and find out where the weak links are, where the slowdowns are, where the obstacles are, where the bottlenecks are, because we put forecast together based on commercialization dates. And if it's within our control, we've got to fix those. But nothing specific to any one segment across the landscape, just internal misses. As Mike said, we have visibility of the orders. We have visibility to what's supposed to launch. We missed – internally we missed it.
William Austen: Yeah. Anthony, this is Bill. What Mike tried to layout in his prepared remarks was our workforce is now in Oshkosh. They run the equipment effectively. What the team in healthcare was probably overly aggressive at when they put the plan together was thinking that the workforce would be able to establish the same kind of productivity that a veteran operator and veteran operators establish over a 20-year window. So, once the operators learn the product specifications, not just how to run the equipment, but how better to run each spec, that's how you drive productivity. Our team in healthcare was probably overly aggressive thinking that a new workforce would understand how to do that quicker. We're going to be able to get through that in 2017, but we're still going to be working through the productivity issues in 2017. Sequentially, that facility continues to improve, throughput is going up, quality is going up, scrap and waste are going down. Now, as the operators become more and more familiar with the product side, we'll start to drive more productivity and that will happen as we go through 2017.
William Austen: Yeah. Scott, this is Bill. We didn't have this issue last year. We have visibility to orders. We have visibility to product launches. What we're understanding and finding out is that there is a way too many handoffs and way too many touches in the process of taking the customer order, getting it through graphics, getting it scheduled, getting it into a plant, running a truck. There is way too many touches, way too many handoffs, way too many bottleneck. That's what we're understanding and now we're bringing in the consultant to help us streamline that, take out those touches, take out those handoffs, get rid of the bottlenecks.
William Austen: With the change in the capital deployment, CapEx deployment process that we've put in place, we're already working on 2017 CapEx now. So we anticipate around the $200 million CapEx for 2017.
William Austen: Yeah. Mark, this is Bill. I was just there, spent a week down there, going through the restructuring program with the team, visited both of the plants that have been expanded. They've both been completed. We're now starting to move equipment and products from the facility that will be closed into the new facilities. There is a much – where I have been anyway, okay, and I was also spent – I had a dinner with 80 of our top customers down there. I would be on the side of there is a sense of encouragement in Brazil. I'm not going to say it's all kinds of optimism, but there is a sense that things are improving across Brazil. That's the sense I got from visiting the facilities, talking with our folks as well as meeting with 80 of our top customers.
William Austen: Yeah. The delays we saw initiated from customers were along the lines of new lines in their plant that were coming up, new kinds of products that they were going to be delivering to the market. They hadn't gotten those lines up to the rates they wanted. They hadn't debugged those lines yet. So that's been done through the third quarter. We're now starting to begin to ship some of those units to those new plants. So it's not a function of their end market.
William Austen: Phil, it's the latter. We feel good about the longer-term as long as we shore up the issues we have today.
William Austen: And we're on top on that. You should know that. We're bringing in that consultant to help us do it and we've got new leadership in the healthcare business.
William Austen: Yeah. Let me talk a little bit about that. If you look over the first nine months of 2016, LatAm is flat, okay. So, we're doing some good things down there to maintain flat in that environment. Quarter-to-quarter some is up, some down but for the nine months it's flat. Asia Pacific is up high-single-digits and you've got Europe which is somewhat flat to down a little bit, but that's on a very small base for us. And if you look at our healthcare business, that's doing quite well, up mid-single to mid-high-digits – single-digits rather, so doing well across those environments. Brazil, due to consumption, we're maintaining a flat – we're maintaining flat volumes.
William Austen: Jason, we wouldn't call out the commercialization due to innovation and/or recap. It's just business that has come in. If you look at how we look at the business today, recap drives innovation, innovation drives recap. We can run a new, innovative product across the new recapped assets. So, it's all part of the volume miss that we had in Q3 in the commercialization. It's not necessarily associated to new product or old product. And if you look at some of the recent launches that we've had that we'll carry through into Q4 and into 2017, we've been able – as we talk about becoming more of a global operating company, we have done a really nice job of starting to move specifications around the world to drive growth in our Global Packaging business quite steadily.
William Austen: Yes. The specific project we have the consulting coming in on is for the commercialization within U.S. Packaging.
William Austen: Yeah. On a quarter-to-quarter basis, we might have some customers and segments that are up, some customers that are and segments that are down. Over the longer-term, we're continuing to work the recapitalization process to drive new volume, okay. It doesn't matter to us what segment it comes in. It gives us the ability to lower the watermark on what our costs are, so we can be competitive across a wide variety of segments. Whether it's meat, cheese, dairy or bakery or confection, we're gaining volume and business. And that's why we say we have this visibility to the orders and why it's so frustrating that we can't get products commercialized because we have the orders in hand. We disappoint ourselves when that happens. We also disappoint the customer. But it's not – we look at the whole business as flexible packaging, not any one segment.
William Austen: Our goal is to maintain the 15% product vitality in U.S. and to continue to drive it higher in Global because we can transfer specs faster to Global to gain share.
William Austen: Adam, we should and can drive 2% volume going forward. We have the ability to do that. There are a lot of – there is many opportunities and businesses and segments that we are not in that we're getting into through the recapitalization efforts. It's on us to make that happen. It's about the big middle, as we talked before. The top of the triangle, a high-barrier meat/cheese, processed meats is not necessarily growing. It's the big middle where the opportunity lies in conversion from glass and cans to flexible packaging. With more and more formats coming out there all the time, some of the wins that we've had throughout this year, throughout 2016 come in that category. So, we're not going to back off and we're not going to let the team off the hook, okay, for not growing that business when we have the tools, we have the people, we've got the assets in place to make that 2% happen.
William Austen: Chris, the recap process has absolutely helped that, okay. If you look at some of this business that we should have commercialized in Q3, its business that we had years ago that's now coming back and we couldn't get it commercialized. If you wanted to – the picture is, is that that's the volume that should be ours and we're going to get it. We're out there getting it. We couldn't get it through our system. That's the problem. That has to get fixed.
William Austen: Yes. The latter part, Chris, I'll talk about briefly, is that meat, cheese category, what we used to call meat, cheese. A lot of that meat, cheese now is converting to what's called snacking. We used to look at in the past snacking as salty snacks, right, crackers, chips, cookies. That's not the kind of snacking that we talk about today. Snacking today is high-barrier snacking. So it's in that top part of the triangle and it's helping us to expand margins there. And that's some of the struggles that some of our customers have had in bringing their plants up to speed to go after this new category because it's a much different package architecture and a much different product than what they are traditionally been running. So that's helping and growing the big middle in what we would call the grocery, consumer and industrial category is what's helping us to feed that volume and give us visibility to this volume that's coming that we couldn't get commercialized. And some of that is in the non-food space.
William Austen: George, we have comfort on the visibility of the 2%. If you look at some of the miss that we had in Q3, it is now shipping in Q4 because we missed it in Q3. So, we have comfort on the 2%. It's still an aggressive number for the team to make, but you're not going to let them off the hook. They've got plans in place to continue to run, to get that volume out.
William Austen: Sure. I'll answer that one first, Mark. We have shut facilities down. We've doubled the size of the workforce in this one facility. We did it at a time when the labor force in this area just got squeezed tremendously. And we've waited through the building process, meaning expanding, doubling the size of the plant to bring the workforce in towards the tail end of the facility being completed. In hindsight, we should have backed that up several months to bring labor in sooner, send them to the facility that was being closed, to get trained at the facility that was being closed. We had some issues with union, non-union. We didn't want to do that. But in hindsight, we probably should have done that anyway. We brought in some totally new equipment at a time when labor was extremely tight. And we could not get qualified labor to stick around and run the new equipment. Hindsight, lesson learned, bring the labor in quicker, get him to the facility that you're bringing down to train and learn ahead of schedule.
George Staphos: Thanks, operator. Hi, everyone. Good morning. Thanks for the details so far. I guess my first question is around volume. One, I just wanted to understand a little bit more clearly, Mike or Bill, what you're referring to in terms of the – I think you said 2% volume shortfall relative guidance in the third quarter and fourth quarter. And you then mentioned that, I think, the fourth quarter midpoint of your guidance assumes 2% volume growth. If I incorrectly phrase those, please correct me, otherwise if you can provide a little bit more color around that and why the 2% goal in the fourth quarter would be realistic? Thank you.
George Staphos: Hi, everyone. Thanks for taking my follow-ons. I wanted to drill back into the volume outlook. And if we look at the narrative this year, guys, despite best intentions, you thought you're going to hit a much higher volume growth. It sounds like, to use your term, you worded down for the investment community hoping to do at least as well if not better and obviously put some cushion into the model for the unforeseen. Thus far volumes have been less than you would have anticipated. And that is what it is. So as we hear you say, you've got a 2% volume target for next year – excuse me, for this coming fourth quarter, on the one hand, you say you have it in your book of business, but you're not so sure about the commercialization, from Erin's comment earlier to one of the questions. So is the 2% the number, but can't stand a watered down to be hit? I didn't phrase that the right way. But, in other words, is there any cushion in that? Or do you – is your book of business a lot larger and that's why you have comfort on the 2%? And then I had a follow-on.
George Staphos: Thanks, guys. Just trying to go in sequence here. I guess my last question is how sustainable is the reduction that we've seen in SG&A and corporate and recognizing that you'll probably say that you feel pretty good about it, in light of also the need to continue to commercialize, hit the market, try to more effectively grow top-line? Should the third quarter trend that we've seen be sustained a lot of your volume growth expectations? Thanks guys and good luck in the quarter.
Michael Clauer: George, when we gave guidance for the second half of the year, the assumption was – the forecast was we were going to have 2% volume growth in Q3 and 4% in Q4. We told – externally we watered it down and said we would be up 1.5%. We didn't hit that in Q3 and we're going down Q4 from 4% to 2%. And, again, we have a lot of visibility into what should be commercialized and be happening in Q4.
Michael Clauer: I think last year, Scott, some of our problems were just our customers making business decisions, which they were losing volumes in the markets. This year – we really have been – the recapitalization program has really allowed us to really kind of get some new business coming in. And I don't want you to think that all this new businesses at the top of the pyramid is -
Michael Clauer: It's in the big middle. And we forecast these things to start happening at a certain point in time and then they don't. And they don't because of some of our inabilities to get the stuff commercialized, meaning getting it made and getting it shipped to our customer. And that's what Bill was referring to, is that we, as outside organization, is going to come in and surgically evaluate our process and look for all the ways we can improve this process and take time out of it.
Michael Clauer: And if you recall the lead times, a lot of our recapitalization and growth initiatives are a year to 18 months where money spent in 2018 has pretty much already been approved and worked – 2017, I'm sorry.
Michael Clauer: Well, on the restructuring, main facility will be closed by the end of the year. I think we've – assuming we're going to get about three quarters of those benefits in 2017 with one – the major facility will be effective by January 1. So that's how I would kind of think about that. And as far as healthcare is concerned, right now, we're probably in Q3. We're probably about a $1 million give or take worse than we wanted, worse than the original projections, albeit we were better. I think we're still thinking Q4 will be comparable to that. And then how I would think about next year is clearly there's some year-over-year improvement just from the standpoint we've gone from the $0.02 down to a $0.01. But that's how I kind of think about it, is maybe we get back half to two-thirds of what would be disappointing to ourself as we go through 2017.
Michael Clauer: The reason I didn't change the range is because a function of that cash is really coming from improving primary working capital. And if you really think through it your Q4 EBITDA in theory doesn't really turn into cash until Q1, give or take a month. So that's the reason I kept the guide and I'm pretty comfortable that we're going to be within that range.
Michael Clauer: There is a lot going on right now and the multiples are kind of like the public packaging companies. There's an expectation that they're up, close to 10%. And clearly for a healthcare asset, we would do that. For a packaging asset, probably not. We'd be thinking more eight times to nine times. So that's the way I kind of think about M&A. And then, with the addition of Jim, I think, we've done a pretty good job of kind of nurturing the types of companies we want to own that we know. I'm really looking forward to Jim helping us kind of understand what we don't know and where we also should be looking for potential acquisitions or joint ventures.
Michael Clauer: Yeah. The original working capital additional improvement we targeted was $50 million to $75 million. What I mentioned at the end of Q2 was it didn't feel like the pace we were getting that improvement was and I kind of fold it down for 2016 and said we're not giving up on it. We'll get in 2017. So at this point in time, we feel like we're going to get about $25 million to $35 million of that improvement, which still says if you go back to the original $50 million to $75 million there is an additional $25 million plus to get in 2017. And that wasn't specific on it being in Q1. It will be in 2017.
Michael Clauer: I think we still have short-term some opportunity in payables. And that's kind of when I'm talking more about payables, when we're talking about trying to get improved – additional improved terms there. Accounts receivable, I think, we do a pretty good job there and that's one that's going to – our currency levels, percent current is very high, always has been. And then we have an opportunity in inventory, but that's more once we get onto our new ERP platform by the end of 2017. I really think that the focus of that platform as some of the tools we're putting in is to go after WIP, by taking lead times out of the business. And that will be a further opportunity for us in the U.S.
Michael Clauer: I said the 2% is the midpoint of our range, okay. So, you can make an assumption there that the bottom end is probably flat and the upper end is better than 2%.
Michael Clauer: It was about $0.04, would be about $6 million of OP. Assuming that everything else is constant that would be the number. And then in healthcare I believe the number is $8 million to $9 million for the year. And I think my comment would be and I think we're probably comfortable that we're going to at least get half of that back next year.
Michael Clauer: Everything else constant, right. There is other puts and takes that are always going to hit any business.
Michael Clauer: That would go up. Commercial paper was at, what, 80 basis points at 3% on $300 million, so you can do that math. It's, what, $4 million, something like that.
Michael Clauer: I can answer that. I mean we're going to stick with what we've been saying all along. We are trying to figure out how to hold SG&A dollars flat over a long period of time. And don't make an assumption that the commercialization process is a function of not enough people. It could be a function of too many people. So, that's how I kind of look at it. We're not going to shortcut anything, but I'm not a big believer that everything is always about more. Sometimes it's less, improves the process.
Michael Clauer: And it's a little – for the full year, it's in the neighborhood of about $0.03 a share is the benefit. And we haven't really gotten a lot of synergies yet because of the time it takes to get things qualified. I'm going to have to qualify a piece of equipment in Puerto Rico and move it there. So those benefits are coming next year. And if you recall, we did not acquire the plant in Florida or the plant in Malaysia. What we did is we signed a transition service agreement where they make it for us and ship it.
Michael Clauer: And at one point in time unless we move the equipment we get that benefit and that will be occurring as we go through next year.
